Color-graded pictogram label to reduce medicine-related traffic crashes found ineffective
A new study questions the effectiveness of using pictogram message on the labels of anxiety and sleep medications that interfere with driving – an approach this is currently implemented across France. The British Journal of Clinical Pharmacology study found that the risk of being responsible for a crash associated with these medicines did not decrease long-term after the pictogram was introduced.
A decade ago, France introduced a color-graded pictogram that was placed on the outer packaging of all medicines classified as being at risk for driving. Three increasing risk levels were defined and identified on packaging with a color code (yellow, orange, and red) and instructions for driving (be careful, be very careful, and danger: do not drive). To determine the impact of this change on traffic crashes, a team led by Ludivine Orriols, PhD and Emmanuel Lagarde, PhD of the University of Bordeaux analyzed information from three French national databases and matched it to the national health care insurance database, police reports, and the national police database of injurious crashes.
Drivers involved in an injurious crash in France from July 2005 to December 2011 were included in the analysis, and the study was divided into four time periods: 1) July 2005 to December 2006 corresponded to a period during which the pictogram was not yet set up; 2) January 2007 to May 2008 was used to estimate the impact of the introduction of the pictogram; and 3) June 2008 to December 2009 and 4) January 2010 to December 2011 were both defined to assess any relapse in the potential impact of the pictogram. The three drug classes considered were those with the most consistent evidence for a causal association with the risk of road traffic crashes: benzodiazepine anxiolytics, benzodiazepine hypnotics, and z-hypnotics. These drugs are commonly prescribed to treat anxiety disorders or induce sleep.
The investigators identified 69,353 responsible and 73,410 non-responsible drivers involved in an injurious crash during the study period. Use of benzodiazepine anxiolytics was associated with a 42 percent increased likelihood of being responsible for a road traffic crash during the pre-intervention period. The increased risk disappeared after introduction of the pictogram but became significant again in later time periods (19 percent and 35 percent increased risks in periods 3 and 4, respectively). This trend was similar for benzodiazepine hypnotics, although fewer individuals took these drugs, making the results insignificant. Even worse, the risk of being responsible for a crash increased in users of z-hypnotics across the study period (with 24, 32, and 32 percent increased risks in periods 2, 3, and 4, respectively).
The findings question the efficacy of the measure for promoting awareness about the effect of medicines on driving abilities. "We estimated that medicinal drug consumption is responsible for around three percent of road traffic crashes," said Dr. Orriols. "Prevention policies should be revisited towards the general driving population but also towards healthcare professionals, including general practitioners and pharmacists," added Dr. Lagarde.
For more information or to obtain a PDF of any study, please contact [email protected]
Full citation:"Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study." Ludivine Orriols, Audrey Luxcey, Benjamin Contrand, Blandine Gadegbeku, Bernard Delorme, Aurore Tricotel, Nicholas Moore, Louis-Rachid Salmi, and Emmanuel Lagarde. British Journal of Clinical Pharmacology. Published Online: August 22, 2016, DOI: 10.1111/bcp.13075.
URL Upon Publication: http://doi.wiley.com/10.1111/bcp.13075 Author Contact: To arrange an interview with the author, please contact Priscille Riviere, Deputy Head of Inserm's Press Office, at [email protected] or +33 (0)1 44 23 60 73.
About the Journal: The British Journal of Clinical Pharmacology has the primary goal of publishing high quality research papers on all aspects of drug action in humans. The journal has a wide readership, bridging the medical profession, clinical research and the pharmaceutical industry, and is published monthly. It is owned by the British Pharmacological Society and published by Wiley. The journal's current Impact Factor is 3.83 (Thomson Reuters Science Citation Index).
About The British Pharmacological Society: The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Founded in 1931, it is now a global community at the heart of pharmacology, with over 3,500 members from more than 60 countries worldwide. The Society leads the way in the research and application of pharmacology around the world through its scientific meetings, educational resources and peer-reviewed journals: the British Journal of Clinical Pharmacology, Pharmacology Research & Perspectives and the British Journal of Pharmacology, which includes the Concise Guide to PHARMACOLOGY, featuring open access overviews of the key properties of over 1,700 human therapeutic targets and their drugs, and links to http://www.guidetopharmacology.org.
Press Office: +44 20 7239 0180 | M. +44 7786 552498 | E. [email protected]
About Wiley: Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Developmentsegment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.wiley.com.